ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1199

A Genome-Wide Association Study of Methotrexate-Pneumonitis in Rheumatoid Arthritis: Results from the Pneumonitis Study Consortium

James Bluett1, Sally-Ann Owen1, Jonathan Massey2, Darren Plant2, Munir Pirmohamed3, Suzanne M.M. Verstappen4 and Anne Barton5,6, 1Arthritis Research UK Centre for Genetics and Genomics, The University of Manchester, Manchester, United Kingdom, 2NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester Academy of Health Sciences, Manchester, United Kingdom, 3Institute of Translational Medicine, The University of Liverpool, Liverpool, United Kingdom, 4Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, 5NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester Academic Health Science Centre, Manchester, United Kingdom, 6Arthritis Research UK Centre for Genetics and Genomics, Centre for Musculoskeletal Research, University of Manchester, Manchester, UK, Manchester, United Kingdom

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Adverse events, GWAS, lung injury and methotrexate (MTX)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 14, 2016

Title: Genetics, Genomics and Proteomics - Poster II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Methotrexate (MTX) is associated with a rare but potentially life-threatening lung disease, MTX-pneumonitis (MTX-P). MTX-P is an idiosyncratic hypersensitivity reaction to MTX inducing inflammation, cytokine release and the activation of CD4+ T-lymphocytes within the lung parenchyma. Clinical risk factors are associated with the development of MTX-P; they are however, poorly predictive, there is therefore a need for improved markers of disease susceptibility. Epidemiological studies have provided evidence that MTX-P may be a genetically susceptible disease. To date, only one locus has been associated with MTX-P in a Japanese population (HLA-A 31:01). To identify genetic predictors of MTX-P we conducted a genome wide association study in a United Kingdom (UK) population.

Methods: Cases of MTX-P were recruited from a UK-wide multi-centre study. Cases were physician diagnosed MTX-P. Controls were recruited from the Rheumatoid Arthritis Medications Study (RAMS), a multi-centre observational study in the UK. Controls were participants with RA taking MTX for at least 1 year without the development of MTX-P and were age:sex matched 3:1 to cases. Genotyping was performed using the Illumina Infinium HumanCoreExome BeadChip array (Illumina, San Diego, USA). Bioinformatic analysis was undertaken to identify associated SNPs with potential functional significance.

Results: 65 cases and 195 controls were recruited. The study has an 80% power to detect an allele with frequency 0.30 and allelic odds ratio of 3.0. Following quality control, data for 236,308 SNPs in 62 cases and 172 controls remained. 48 cases (77%) retrospectively fulfilled either the Carson et al. or Searles et al. unvalidated criteria for MTX-P. Three SNPs were associated with MTX-P at P<10-5. Rs6593803 (p = 1.85 X 10-7, OR = 3.13) maps near GJA5 (figure 1), rs9299346 (p = 1.76 X 10-6, OR = 2.76) in GRIN3A and rs1624005 (p = 6.54 X 10-6, OR = 2.59) maps near LRFN5. rs6593803 affects GJA5 expression, a subunit of the gap junction connexin 40. Transgenic mice deficient in connexin 40 and 43 (cx40– –/cx43– –) have a reduced life span due to lung abnormalities including pulmonary fibrosis, alveolar wall thickening and increased lung fibroblasts, histopathological findings similar to MTX-P.

Conclusion: 3 SNPs were associated with MTX-P at borderline significance levels. Further studies should prioritise investigating the role of rs6593803 in MTX-P.

 

rs6593803.bmp

Figure 1. LocusZoom plot of SNP rs6593803.  


Disclosure: J. Bluett, None; S. A. Owen, None; J. Massey, None; D. Plant, None; M. Pirmohamed, None; S. M. M. Verstappen, None; A. Barton, None.

To cite this abstract in AMA style:

Bluett J, Owen SA, Massey J, Plant D, Pirmohamed M, Verstappen SMM, Barton A. A Genome-Wide Association Study of Methotrexate-Pneumonitis in Rheumatoid Arthritis: Results from the Pneumonitis Study Consortium [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/a-genome-wide-association-study-of-methotrexate-pneumonitis-in-rheumatoid-arthritis-results-from-the-pneumonitis-study-consortium/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-genome-wide-association-study-of-methotrexate-pneumonitis-in-rheumatoid-arthritis-results-from-the-pneumonitis-study-consortium/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology